Genomic-guided precision therapy for soft tissue sarcoma
Journal
ESMO Open
Journal Volume
5
Journal Issue
2
Date Issued
2020
Author(s)
Chen H.-W.
Abstract
Soft tissue sarcoma (STS), although heterogeneous in histopathology presentation, has mostly been treated with chemotherapy agents as one entity. Our understanding of crucial genomic alterations in different STS histologies and the advent of molecular-targeted agents have reshaped the treatment paradigm for advanced STS. Small-molecule inhibitors of c-KIT, plate-derived growth factor receptor alpha, c-MET, BRAF, anaplastic lymphoma kinase, ROS1 and colony-stimulating factor-1 receptor have been successfully validated in clinical studies to yield practice-changing results. Inhibitors of other novel genomic targets including mouse double minute 2 homolog, cyclin-dependent kinase 4/6, mitogen-activated protein kinase and epigenetic regulators are expected to be developed in the near future. Furthermore, with the advancement and accessibility of molecular diagnosis and next-generation sequencing, a genomic-based therapeutic approach should be widely applicable to advanced STS patients. This review will focus on the progress of genomic-guided therapy tailored to each molecular alteration of different STS histologies. ? Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Subjects
genomics; precision medicine; sarcoma
SDGs
Other Subjects
anaplastic lymphoma kinase; antineoplastic agent; B Raf kinase; cyclin dependent kinase 4; cyclin dependent kinase 6; cyclin dependent kinase inhibitor; mitogen activated protein kinase; platelet derived growth factor alpha receptor; protein MDM2; scatter factor receptor; stem cell factor receptor; transcription factor EZH2; tuberin; antineoplastic activity; cancer therapy; dermatofibrosarcoma protuberans; enzyme inhibition; gastrointestinal stromal tumor; gene mutation; genomics; giant cell tumor of tendon sheath; histopathology; human; molecular diagnosis; molecular fingerprinting; molecularly targeted therapy; nonhuman; perivascular epithelioid cell tumor; personalized medicine; plasma cell granuloma; Review; soft tissue sarcoma; genomics; pathology; personalized medicine; procedures; sarcoma; Genomics; Humans; Precision Medicine; Sarcoma
Publisher
BMJ Publishing Group
Type
review